Bobby Gaspar Ph.D., M.D.
Net Worth
Last updated:
What is Bobby Gaspar Ph.D., M.D. net worth?
The estimated net worth of Dr. Bobby Gaspar Ph.D., M.D. is at least $3,562,050 as of 1 Apr 2022. He has received compensation worth at least $3,562,050 in Orchard Therapeutics plc.
What is the salary of Bobby Gaspar Ph.D., M.D.?
Dr. Bobby Gaspar Ph.D., M.D. salary is $712,410 per year as Chief Executive Officer, Member of Scientific Advisory Board & Executive Director in Orchard Therapeutics plc.
How old is Bobby Gaspar Ph.D., M.D.?
Dr. Bobby Gaspar Ph.D., M.D. is 60 years old, born in 1965.
What stocks does Bobby Gaspar Ph.D., M.D. currently own?
As insider, Dr. Bobby Gaspar Ph.D., M.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Orchard Therapeutics plc (ORTX) | Chief Executive Officer, Member of Scientific Advisory Board & Executive Director | 366,158 | $0 | $0 |
What does Orchard Therapeutics plc do?
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
Bobby Gaspar Ph.D., M.D. insider trading
Orchard Therapeutics plc
Dr. Bobby Gaspar Ph.D., M.D. has made only one insider trade between 2020-2022, according to the Form 4 filled with the SEC. He purchased 15,000 units of ORTX stock worth $11,085 on 1 Apr 2022.
As of 1 Apr 2022 he still owns at least 366,158 units of ORTX stock.
Orchard Therapeutics key executives
Orchard Therapeutics plc executives and other stock owners filed with the SEC:
- Dr. Bobby Gaspar Ph.D., M.D. (60) Chief Executive Officer, Member of Scientific Advisory Board & Executive Director
- Mr. Frank E. Thomas (55) Pres & Chief Operating Officer